127 related articles for article (PubMed ID: 29246618)
21. Phenoconversion from Spastic Paraplegia to ALS/FTD Associated with
Theuriet J; Pegat A; Leblanc P; Vukusic S; Cazeneuve C; Millecamps S; Banneau G; Guillaud-Bataille M; Bernard E
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946825
[TBL] [Abstract][Full Text] [Related]
22. Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia.
Schüle R; Brandt E; Karle KN; Tsaousidou M; Klebe S; Klimpe S; Auer-Grumbach M; Crosby AH; Hübner CA; Schöls L; Deufel T; Beetz C
Neurogenetics; 2009 Apr; 10(2):97-104. PubMed ID: 18855023
[TBL] [Abstract][Full Text] [Related]
23. Sensory ataxia as a prominent clinical presentation in three families with mutations in CYP7B1.
Di Fabio R; Marcotulli C; Tessa A; Leonardi L; Storti E; Pierelli F; Santorelli FM; Casali C
J Neurol; 2014 Apr; 261(4):747-51. PubMed ID: 24519355
[TBL] [Abstract][Full Text] [Related]
24. [Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Martínez-Abundis E; Barrera-Durán C; González-Ortiz M; Hernández-Salazar E
Gac Med Mex; 2016 Oct; 152(Suppl 2):88-95. PubMed ID: 27792720
[TBL] [Abstract][Full Text] [Related]
25. Novel mutations in the CYP7B1 gene cause hereditary spastic paraplegia.
Cao L; Fei QZ; Tang WG; Liu JR; Zheng L; Xiao Q; He SB; Fu Y; Chen SD
Mov Disord; 2011 Jun; 26(7):1354-6. PubMed ID: 21452256
[No Abstract] [Full Text] [Related]
26. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
27. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
28. CYP7B1 mutations in French-Canadian hereditary spastic paraplegia subjects.
Noreau A; Dion PA; Szuto A; Levert A; Thibodeau P; Brais B; Dupré N; Rioux MF; Rouleau GA
Can J Neurol Sci; 2012 Jan; 39(1):91-4. PubMed ID: 22384504
[No Abstract] [Full Text] [Related]
29. CYP7B1: novel mutations and magnetic resonance spectroscopy abnormalities in hereditary spastic paraplegia type 5A.
Roos P; Svenstrup K; Danielsen ER; Thomsen C; Nielsen JE
Acta Neurol Scand; 2014 May; 129(5):330-4. PubMed ID: 24117163
[TBL] [Abstract][Full Text] [Related]
30. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
Hernandez-Mijares A; Bañuls C; Rovira-Llopis S; Diaz-Morales N; Escribano-Lopez I; de Pablo C; Alvarez A; Veses S; Rocha M; Victor VM
Atherosclerosis; 2016 Apr; 247():40-7. PubMed ID: 26868507
[TBL] [Abstract][Full Text] [Related]
31. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Maddox TM; Tang F; Downs JR; Masoudi FA; Virani SS; Daugherty SL; Rumsfeld JS
JAMA Intern Med; 2017 Jun; 177(6):887-889. PubMed ID: 28437531
[TBL] [Abstract][Full Text] [Related]
32. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
33. [Letter].
Poli A
G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
[No Abstract] [Full Text] [Related]
34. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
[TBL] [Abstract][Full Text] [Related]
35. [The IMPROVE-IT trial].
Menozzi A; Lina D; Urbinati S; Greco C
G Ital Cardiol (Rome); 2015 Dec; 16(12):667-71. PubMed ID: 26667942
[No Abstract] [Full Text] [Related]
36. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Weingärtner O; Sijbrands EJG; Lütjohann D
JAMA Cardiol; 2020 Feb; 5(2):234. PubMed ID: 31895451
[No Abstract] [Full Text] [Related]
37. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Li D; McCaw ZR; Wei LJ
JAMA Cardiol; 2020 Feb; 5(2):235. PubMed ID: 31895431
[No Abstract] [Full Text] [Related]
38. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Bach RG; Cannon CP; Blazing MA
JAMA Cardiol; 2020 Feb; 5(2):235-236. PubMed ID: 31895449
[No Abstract] [Full Text] [Related]
39. Mutational analysis of the CYP7B1, PNPLA6 and C19orf12 genes in autosomal recessive hereditary spastic paraplegia.
Schubert SF; Hoffjan S; Dekomien G
Mol Cell Probes; 2016 Feb; 30(1):53-5. PubMed ID: 26714052
[TBL] [Abstract][Full Text] [Related]
40. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Vega GL; Weiner MF; Lipton AM; Von Bergmann K; Lutjohann D; Moore C; Svetlik D
Arch Neurol; 2003 Apr; 60(4):510-5. PubMed ID: 12707064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
